These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: [Peripheral blood stem cell transfusion for a patient with RAEB-T].
    Author: Fujii H, Nakagawa H, Sonoda Y, Kuzuyama Y.
    Journal: Rinsho Ketsueki; 1993 Jun; 34(6):764-8. PubMed ID: 7690075.
    Abstract:
    This report deals with a case of RAEB in transformation (RAEB-T) who received peripheral blood stem cell transfusion (PBSCT) and has remained in complete remission for 15 months. A 51-year-old man was admitted to our hospital with abnormal hematological examinations in August 1991. Peripheral blood showed a WBC of 3,580/microliters with 19% myeloblasts. Bone marrow aspirate revealed slight hypocellularity with 21.2% myeloblasts. Many of these myeloblasts contained Auer rods. He was diagnosed as having RAEB-T. He was treated with low dose Ara-C, followed by the BHAC-VEP regimen and complete remission was obtained 2 months later. After high dose Ara-C regimen, one leukapheresis was performed using CS-3000 during bone marrow recovery. The collected number of CFU-GM, BFU-E and CFU-mix were 4.3, 4.3 and 0.68 x 10(5)/kg b.w., respectively and they were cryoreserved. In November 1991, 16 mg/kg b.w. of busulfan, 120 mg/kg b.w. of cyclophosphamide and rG-CSF were used as a conditioning regimen and PBSCT was performed. The infused number of CFU-GM, BFU-E and CFU -mix were 0.8, 0.9 and 0.14 x 10(5)/kg b.w., respectively. The number of days to reach 500 neutrophils/microliters and 5 x 10(4) platelets/microliters was 17 and 63 days, respectively. He has remained in complete remission for 15 months after PBSCT. PBSCT appears to be one effective therapeutic choice for the treatment of RAEB-T.
    [Abstract] [Full Text] [Related] [New Search]